转化治疗在结直肠癌肝转移中的研究进展
Research Progress of Conversion Therapy in Colorectal Cancer Liver Metastasis
DOI: 10.12677/ACM.2023.13112428, PDF,   
作者: 殷 栋:青海大学临床医学院,青海 西宁;王海久*:青海大学附属医院肝胆胰外科,青海 西宁
关键词: 结直肠癌肝转移转化治疗Colorectal Cancer Liver Metastases Translational Therapy
摘要: 结直肠癌(colorectal cancer, CRC)在全球发病率位居前列,结直肠癌肝转移(Colorectal liver metas-tases, CRLM)在结直肠癌病程进展中可占据半数以上,目前唯有手术切除可使CRLM患者的达到根治,但仅有不到20%患者初始可行手术切除,针对这一问题,旨为大多数没有手术机会的CRLM患者通过化疗、靶向治疗、局部治疗等方式创造手术机会,转化治疗被提出并应用于临床,本文就转化治疗在CRLM中的进展、治疗方法及疗效做一综述,以期为相关研究提供参考依据。
Abstract: Colorectal cancer (CRC) has one of the highest incidence rates in the world, and colorectal liver me-tastases (CRLM) can account for more than half of the progression of colorectal cancer. Currently, surgical resection is the only option that can lead to the radical cure of CRLM, but less than 20% of the patients have a feasible chance for surgical resection. However, less than 20% of patients are in-itially feasible for surgical resection. In order to address this problem and to create surgical oppor-tunities for the majority of patients with CRLM who do not have surgical opportunities through chemotherapy, targeted therapy, local therapy, etc., the translational therapy has been proposed and applied in the clinic, and this article provides a review of the progress, treatment methods and efficacy of translational therapy in CRLM, with the purpose of providing a reference basis for the relevant research.
文章引用:殷栋, 王海久. 转化治疗在结直肠癌肝转移中的研究进展[J]. 临床医学进展, 2023, 13(11): 17333-17340. https://doi.org/10.12677/ACM.2023.13112428

参考文献

[1] Sung, H., Ferlay, J., Siegel, R.L., et al. (2021) Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 71, 209-249. [Google Scholar] [CrossRef] [PubMed]
[2] De Jong, M.C., Pulitano, C., Ribero, D., et al. (2009) Rates and Patterns of Recurrence Following Curative Intent Surgery for Colorectal Liver Metastasis: An International Multi-Institutional Anal-ysis of 1669 Patients. Annals of Surgery, 250, 440-448. [Google Scholar] [CrossRef
[3] Adam, R., Delvart, V., Pascal, G., et al. (2004) Rescue Sur-gery for Unresectable Colorectal Liver Metastases Downstaged by Chemotherapy: A Model to Predict Long-Term Sur-vival. Annals of Surgery, 240, 644-657. [Google Scholar] [CrossRef] [PubMed]
[4] Timmerman, R.D., et al. (2009) Local Surgical, Ablative, and Radiation Treatment of Metastases. CA: A Cancer Journal for Clinicians, 59, 145-170. [Google Scholar] [CrossRef] [PubMed]
[5] Adam, R., et al. (2009) Patients with Initially Unresectable Colorectal Liver Metastases: Is There a Possibility of Cure? Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 27, 1829-1835. [Google Scholar] [CrossRef
[6] 中国医师协会外科医师分会, 中华医学会外科学分会胃肠外科学组, 中华医学会外科学分会结直肠外科学组, 等. 中国结直肠癌肝转移诊断和综合治疗指南(2023) [J]. 中国临床医学, 2023, 30(1): 166-198.
[7] Haraldsdottir, S., Wu, C., Bloomston, M., et al. (2013) What Is the Optimal Neo-Adjuvant Treatment for Liver Metastasis? Therapeutic Advances in Medical Oncology, 5, 221-234. [Google Scholar] [CrossRef] [PubMed]
[8] 张钰洋, 陈善稳, 王鹏远, 等. 结直肠癌肝转移转化治疗的研究进展[J]. 中华胃肠外科杂志, 2021, 24(1): 85-93.
[9] National Comprehensive Cancer Network (2023) NCCN Clinical Practice Guidelines in Oncology: Colon Cancer. Version 3, 2022.
[10] Van Cutsem, E., et al. (2016) ESMO Consensus Guidelines for the Management of Patients with Metastatic Colorectal Cancer. Annals of Oncology, 27, 1386-1422.
[11] Khattak, M.A., et al. (2012) Survival Differences in Patients with Metastatic Colorectal Cancer and with Single Site Metastatic Disease at Initial Presentation: Results from South Australian Clinical Registry for Advanced Colorectal Cancer. Clinical Colorectal Cancer, 11, 247-254. [Google Scholar] [CrossRef] [PubMed]
[12] Bismuth, H., et al. (1996) Resection of Nonresectable Liver Metas-tases from Colorectal Cancer after Neoadjuvant Chemotherapy. Annals of Surgery, 224, 509-520. [Google Scholar] [CrossRef] [PubMed]
[13] Cai, G.-X. and Cai, S.-J. (2012) Multi-Modality Treat-ment of Colorectal Liver Metastases. World Journal of Gastroenterology: WJG, 18, 16-24. [Google Scholar] [CrossRef] [PubMed]
[14] Fakih, M. (2015) Biologic Therapies in Colorectal Cancer: Indications and Contraindications. American Society of Clinical Oncology Educational Book, 35, e197-e206. [Google Scholar] [CrossRef
[15] Alberts, S.R., Horvath, W.L., Sternfeld, W.C., et al. (2005) Oxaliplatin, Fluorouracil, and Leucovorin for Patients with Unresectable Liver-Only Metastases from Colorectal Cancer: A North Central Cancer Treatment Group Phase II Study. Journal of Clinical Oncology, 23, 9243-9249. [Google Scholar] [CrossRef
[16] Pozzo, C., Basso, M., Cassano, A., et al. (2004) Neoadjuvant Treatment of Unresectable Liver Disease with Irinotecan and 5-Fluorouracil plus Folinic Acid in Colorectal Cancer Pa-tients. Annals of Oncology, 15, 933-939. [Google Scholar] [CrossRef] [PubMed]
[17] 王枭杰, 池畔, 林惠铭, 卢星榕, 黄颖, 徐宗斌, 黄胜辉, 叶道雄. 转移灶不可切除的转移性结直肠癌原发灶切除术疗效的Meta分析[J]. 中华消化外科杂志, 2016, 15(2): 140-146.
[18] 中国医师协会外科医师分会多学科综合治疗专业委员会, 中国抗癌协会大肠癌专业委员会, 沈琳, 顾晋, 金晶. 结直肠癌肺转移多学科综合治疗专家共识(2018版) [J]. 肿瘤综合治疗电子杂志, 2018, 4(4): 1-15.
[19] Ye, L.C., Liu, T.S., Ren, L., et al. (2013) Randomized Controlled Trial of Cetuximab plus Chemotherapy for Patients with KRAS Wild-Type Unresectable Colorectal Liver-Limited Metastases. Journal of Clinical Oncology, 31, 1931-1938. [Google Scholar] [CrossRef
[20] Folprecht, G., Gruenberger, T., Bechstein, W.O., et al. (2010) Tumour Response and Secondary Resectability of Colorectal Liver Metastases Following Neoadjuvant Chemotherapy with Cetuximab: The CELIM Randomised Phase 2 Trial. The Lancet Oncology, 11, 38-47. [Google Scholar] [CrossRef
[21] Karoui, M., Penna, C., Amin-Hashem, M., et al. (2006) In-fluence of Preoperative Chemotherapy on the Risk of Major Hepatectomy for Colorectal Liver Metastases. Annals of Surgery, 243, 1-7. [Google Scholar] [CrossRef] [PubMed]
[22] 朱德祥, 许剑民. 2017年中国临床肿瘤学会年会结直肠癌研究进展解析[J]. 中华消化外科杂志, 2017, 16(11): 1101-1104.
[23] Beppu, T., Emi, Y., Tokunaga, S., et al. (2014) Liver Resectability of Advanced Liver-Limited Colorectal Liver Metastases Following mFOLFOX6 with Bevaci-zumab (KSCC0802 Study). Anticancer Research, 34, 6655-6662.
[24] Shen, C., Hu, H., Cai, Y., et al. (2022) mFOL-FOXIRI with or without Bevacizumab for Conversion Therapy of RAS/BRAF/PIK3CA Mutant Unresectable Colorectal Liver Metastases: The FORBES Non-Randomized Phase II Trial. Annals of Translational Medicine, 10, 171. [Google Scholar] [CrossRef] [PubMed]
[25] Gruenberger, T., Bridgewater, J., Chau, I., et al. (2015) Bevacizumab plus mFOLFOX-6 or FOLFOXIRI in Patients with Initially Unresectable Liver Metastases from Colorectal Cancer: The OLIVIA Multinational Randomised Phase II Trial. Annals of Oncology, 26, 702-708. [Google Scholar] [CrossRef] [PubMed]
[26] De Roock, W., De Vriendt, V., Normanno, N., et al. (2011) KRAS, BRAF, PIK3CA, and PTEN Mutations: Implications for Targeted Therapies in Metastatic Colorectal Cancer. The Lancet Oncology, 12, 594-603. [Google Scholar] [CrossRef
[27] Shi, S.J., Wang, L.J., Wang, G.D., et al. (2013) B7-H1 Ex-pression Is Associated with Poor Prognosis in Colorectal Carcinoma and Regulates the Proliferation and Invasion of HCT116 Colorectal Cancer Cells. PLOS ONE, 8, e76012. [Google Scholar] [CrossRef] [PubMed]
[28] Andre, T., Shiu, K.K., Kim, T.W., et al. (2020) Pembrolizumab versus Chemotherapy for Microsatellite Instability-High/Mismatch Repair Deficient Metastatic Colorectal Cancer: The Phase 3 KEYNOTE-177 Study.
[29] Winer, A., Ghatalia, P., Bubes, N., et al. (2019) Dual Checkpoint Inhibition with Ipilimumab plus Nivolumab after Progression on Sequential PD-1/PDL-1 Inhibitors Pembrolizumab and Atezolizumab in a Patient with Lynch Syndrome, Metastatic Colon, and Localized Urothelial Cancer. The Oncologist, 24, 1416-1419. [Google Scholar] [CrossRef] [PubMed]
[30] Fumet, J.D., Isambert, N., Hervieu, A., et al. (2018) Phase Ib/II Trial Evaluating the Safety, Tolerability and Immunological Activity of Durvalumab (MEDI4736)(anti-PD-L1) plus Tremelimumab (anti-CTLA-4) Combined with FOLFOX in Patients with Metastatic Colorectal Cancer. ESMO Open, 3, e000375. [Google Scholar] [CrossRef] [PubMed]
[31] Shady, W., Petre, E.N., Gonen, M., et al. (2016) Percutane-ous Radiofrequency Ablation of Colorectal Cancer Liver Metastases: Factors Affecting Outcomes—A 10-Year Experi-ence at a Single Center. Radiology, 278, 601-611. [Google Scholar] [CrossRef] [PubMed]
[32] Berber, E., Tsinberg, M., Tellioglu, G., et al. (2008) Resection versus Laparoscopic Radiofrequency Thermal Ablation of Solitary Colorectal Liver Metastasis. Journal of Gastrointesti-nal Surgery, 12, 1967-1972. [Google Scholar] [CrossRef] [PubMed]
[33] De Cobelli, F., Calandri, M., Della Corte, A., et al. (2022) Mul-ti-Institutional Analysis of Outcomes for Thermo Sphere Microwave Ablation Treatment of Colorectal Liver Metastases: The SMAC Study. European Radiology, 32, 4147-4159. [Google Scholar] [CrossRef] [PubMed]
[34] Hong, K., Khwaja, A., Liapi, E., et al. (2006) New Intra-Arterial Drug Delivery System for the Treatment of Liver Cancer: Pre-clinical Assessment in a Rabbit Model of Liver Cancer. Clinical Cancer Research, 12, 2563-2567. [Google Scholar] [CrossRef
[35] Lévi, F.A., Boige, V., Hebbar, M., et al. (2016) Conversion to Resection of Liver Metastases from Colorectal Cancer with Hepatic Artery Infusion of Combined Chemotherapy and Systemic Cetuximab in Multicenter Trial OPTILIV. Annals of Oncology, 27, 267-274. [Google Scholar] [CrossRef] [PubMed]
[36] Martin, R.C.G., Scoggins, C.R., Schreeder, M., et al. (2015) Ran-domized Controlled Trial of Irinotecan Drug-Eluting Beads with Simultaneous FOLFOX and Bevacizumab for Patients with Unresectable Colorectal Liver-Limited Metastasis. Cancer, 121, 3649-3658. [Google Scholar] [CrossRef] [PubMed]
[37] Palma, D.A., Olson, R., Harrow, S., et al. (2020) Stereotactic Ablative Ra-diotherapy for the Comprehensive Treatment of Oligometastatic Cancers: Long-Term Results of the SABR-COMET Phase II Randomized Trial. Journal of Clinical Oncology, 38, 2830. [Google Scholar] [CrossRef
[38] Baltatzis, M. and Siriwardena, A.K. (2019) Liver Resection for Colo-rectal Hepatic Metastases after Systemic Chemotherapy and Selective Internal Radiation Therapy with Yttrium-90 Mi-crospheres: A Systematic Review. Digestive Surgery, 36, 273-280. [Google Scholar] [CrossRef] [PubMed]
[39] Bertens, K.A., Hawel, J., Lung, K., et al. (2015) ALPPS: Challenging the Concept of Unresectability—A Systematic Review. In-ternational Journal of Surgery, 13, 280-287. [Google Scholar] [CrossRef] [PubMed]